Drugs to treat atopic dermatitis are at the top of the FDA’s dermatology list. Biologics and PDE4 inhibitors show promise in the treatment of AD. Approval is still needed for the use of biologics to treat AD in pediatric patients.

Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment

According to researchers, abnormalities in the skin barrier and in the immune system that characterize atopic dermatitis can be reversed by drugs that narrowly target the immune signaling proteins interleukin (IL)-4 and -13.